A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2017
At a glance
- Drugs Umbralisib (Primary) ; Brentuximab vedotin
- Indications Hodgkin's disease
- Focus Adverse reactions
- Sponsors TG Therapeutics Inc
- 30 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Mar 2018.
- 30 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Feb 2018.
- 28 Jun 2017 Planned End Date changed from 1 Jul 2017 to 1 Nov 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History